Hepatitis B reactivation in patients receiving targeted therapies

References

• Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep. 2014;13:235–244. doi: 10.1007/s11901-014-0238-2
   PubMedGoogle Scholar
• Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int. 2011;31(Suppl 1):104–110. doi: 10.1111/j.1478-3231.2010.02396.x
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B. Fact sheet 204. 2015. www.who.int/mediacentre/factsheets/fs204/en.
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592. doi: 10.1016/S0140-6736(09)60207-5
   PubMed Web of Science ®Google Scholar
• Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–1022. doi: 10.1053/gast.2001.22461
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611. doi: 10.1200/JCO.2008.18.0182
   PubMed Web of Science ®Google Scholar
• Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008;8:115–125. doi: 10.1186/1471-2407-8-115
   PubMed Web of Science ®Google Scholar
• Mizuno S, Yamagishi Y, Ebinuma H, et al. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol. 2013;6:188–192. doi: 10.1007/s12328-013-0371-4
   PubMedGoogle Scholar
• Göksu SS. Hepatitis B reactivation related to everolimus. World J Hepatol. 2013;5:43–45. doi: 10.4254/wjh.v5.i1.43
   PubMedGoogle Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–2772. doi: 10.1200/JCO.2012.48.5938
   PubMed Web of Science ®Google Scholar
• Hsu C, Tsou HH, Lin SJ, et al. On behalf of the Taiwan cooperative oncology group. chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–2100. doi: 10.1002/hep.26718
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KK, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842–849. doi: 10.1111/jvh.12402
   PubMed Web of Science ®Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124:3228–3236. doi: 10.1182/blood-2014-06-582346
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581. doi: 10.1056/NEJMoa032534
   PubMed Web of Science ®Google Scholar
• Lee J, Park JY, Huh KH, et al. Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. Nephrol Dial Transplant. 2017;32:722–729. doi: 10.1093/ndt/gfw455
   PubMed Web of Science ®Google Scholar
• Tien YC, Yen HH, Chiu YM. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol. 2017 Mar 31. Available from: http://www.clinexprheumatol.org/abstract.asp?a=11218
   PubMed Web of Science ®Google Scholar
• Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007;85:16–23. doi: 10.1038/sj.icb.7100009
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005;74:254–258. doi: 10.1111/j.1600-0609.2004.00375.x
   PubMed Web of Science ®Google Scholar
• Moses SE, Lim ZY, Sudhanva M, et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol. 2006;78:1560–1563. doi: 10.1002/jmv.20705
   PubMed Web of Science ®Google Scholar
• Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemiae-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45:1363–1367. doi: 10.1111/hepr.12513
   PubMed Web of Science ®Google Scholar
• Nakano N, Kusumoto S, Tanaka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2014;44:354–357. doi: 10.1111/hepr.12117
   PubMed Web of Science ®Google Scholar
• Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemiae-lymphoma patients with resolved HBV infection following systemic chemotherapy. Int J Hematol. 2015;101:398–404. doi: 10.1007/s12185-015-1750-z
   PubMed Web of Science ®Google Scholar
• Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol. 2010;22:443–450. doi: 10.1097/BOR.0b013e328338f6df
   PubMed Web of Science ®Google Scholar
• Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208–217. doi: 10.1016/j.semarthrit.2007.10.011
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. BIOGEAS study group. hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine. 2011;90:359–371. doi: 10.1097/MD.0b013e3182380a76
   PubMed Web of Science ®Google Scholar
• Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006;47:155–157. doi: 10.1080/14639230500236818
   PubMed Web of Science ®Google Scholar
• Thia TJ, Tan HH, Chuah TH, et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J. 2008;49:e86–e89.
   PubMed Web of Science ®Google Scholar
• Lakhani S, Davidson L, Priebat DA, et al. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int. 2008;2:498–499. doi: 10.1007/s12072-008-9099-5
   PubMed Web of Science ®Google Scholar
• Kang BW, Lee SJ, Moon JH, et al. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90:383–387. doi: 10.1007/s12185-009-0386-2
   PubMed Web of Science ®Google Scholar
• Kim SG, Chun JM, Jin R, et al. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc. 2010;42:843–845. doi: 10.1016/j.transproceed.2010.02.038
   PubMed Web of Science ®Google Scholar
• Wang YD, Cui GH, Li M, et al. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl). 2012;125:2636–2637.
   PubMed Web of Science ®Google Scholar
• Lai GM, Yan SL, Chang CS, et al. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol. 2013;19:1318–1321. doi: 10.3748/wjg.v19.i8.1318
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Loré K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473–2479. doi: 10.1182/blood-2004-07-2527
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18:1332–1339. doi: 10.1038/sj.leu.2403401
   PubMed Web of Science ®Google Scholar
• Mohty M, Jourdan E, Mami NB, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood. 2004;103:4666–4668. doi: 10.1182/blood-2003-09-3220
   PubMed Web of Science ®Google Scholar
• Ando T, Kojima K, Isoda H, et al. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379–382. doi: 10.1007/s12185-015-1788-y
   PubMed Web of Science ®Google Scholar
• Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol. 2015;22:430–432. doi: 10.3747/co.22.2665
   PubMed Web of Science ®Google Scholar
• de Jésus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg. 2015;78:424–426.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549. doi: 10.1182/blood-2013-06-507947
   PubMed Web of Science ®Google Scholar
• Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035. doi: 10.1016/S1470-2045(10)70233-3
   PubMed Web of Science ®Google Scholar
• Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian cooperative trial for HaematoOncology (HOVON). Eur J Cancer. 2013;49:3242–3246. doi: 10.1016/j.ejca.2013.06.018
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Takahashi N, Nishiwaki K, et al. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 2013;98:1407–1413. doi: 10.3324/haematol.2013.085167
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522. doi: 10.1182/blood-2013-02-483750
   PubMed Web of Science ®Google Scholar
• Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903–906. doi: 10.3324/haematol.2011.056853
   PubMed Web of Science ®Google Scholar
• Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med. 2009;13:599–601. doi: 10.1111/j.1582-4934.2009.00500_1.x
   PubMed Web of Science ®Google Scholar
• Chen J, Schmitt A, Chen B, et al. Nilotinib hampers the proliferation and function of CD81T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107–2118. doi: 10.1111/j.1582-4934.2008.00234.x
   PubMed Web of Science ®Google Scholar
• Blake S, Hughes TP, Mayrhofer G, et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008;127:330–339. doi: 10.1016/j.clim.2008.02.006
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, et al. Dasatinib exerts an immunosuppressive effect on CD81T cells specific for viral and leukemia antigens. Exp Hematol. 2008;36:1297–1308. doi: 10.1016/j.exphem.2008.05.002
   PubMed Web of Science ®Google Scholar
• Fraser CK, Blake SJ, Diener KR, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD41 and CD81 T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 2009;37:256–265. doi: 10.1016/j.exphem.2008.09.013
   PubMed Web of Science ®Google Scholar
• Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484–2491. doi: 10.1158/1078-0432.CCR-07-4393
   PubMed Web of Science ®Google Scholar
• Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668–679. doi: 10.3109/10428194.2010.550074
   PubMed Web of Science ®Google Scholar
• Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323–370. doi: 10.1146/annurev.immunol.20.100201.131730
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122:227–238. doi: 10.1182/blood-2012-11-465039
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307. doi: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15:1661–1666. doi: 10.1093/annonc/mdh430
   PubMed Web of Science ®Google Scholar
• Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55–59. doi: 10.1046/j.1352-0504.2003.00467.x
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–1311. doi: 10.1038/sj.bjc.6601699
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. doi: 10.1002/hep.23190
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. doi: 10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185. doi: 10.1016/j.jhep.2012.02.010
   PubMed Web of Science ®Google Scholar